LeMaitre Vascular, Inc. (NASDAQ:LMAT) Holdings Raised by Rhumbline Advisers

Rhumbline Advisers boosted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 75,661 shares of the medical instruments supplier’s stock after purchasing an additional 825 shares during the period. Rhumbline Advisers owned approximately 0.34% of LeMaitre Vascular worth $6,971,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. DF Dent & Co. Inc. raised its position in LeMaitre Vascular by 26.2% in the third quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after acquiring an additional 53,797 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in shares of LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock worth $183,769,000 after purchasing an additional 36,850 shares during the last quarter. Rice Hall James & Associates LLC grew its stake in shares of LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock worth $24,273,000 after purchasing an additional 35,383 shares during the last quarter. F M Investments LLC raised its holdings in shares of LeMaitre Vascular by 36.6% in the 3rd quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock worth $11,476,000 after purchasing an additional 33,087 shares in the last quarter. Finally, Barclays PLC lifted its stake in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock valued at $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LMAT. Barrington Research raised their price objective on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research note on Thursday, February 13th. They set an “equal weight” rating and a $95.00 target price for the company. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

LeMaitre Vascular Stock Up 1.9 %

Shares of NASDAQ:LMAT opened at $104.00 on Wednesday. LeMaitre Vascular, Inc. has a twelve month low of $61.09 and a twelve month high of $109.58. The company has a market cap of $2.34 billion, a price-to-earnings ratio of 56.83, a PEG ratio of 2.22 and a beta of 0.96. The business has a 50 day moving average price of $96.23 and a 200 day moving average price of $94.42.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.